Navigation Links
Interleukin Genetics Receives Approval To Sell its PST(R) Periodontal Disease Genetic Test in New York
Date:12/7/2009

WALTHAM, Mass., Dec. 7 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today it has received approval by the State of New York's Department of Health for the Company to sell in New York its PST Genetic Test that determines predisposition to severe periodontal disease in individuals. The test has been available in all other States in the U.S. However, through its Clinical Laboratory Evaluation Program (CLEP), New York monitors the accuracy and reliability of results of laboratory tests, including genetic tests, on specimens obtained within the state, setting one of the highest accreditation standards in the country for genetic testing companies.

Interleukin Genetics currently distributes its PST genetic test to dentists through a licensing agreement with OralDNA Labs, a subsidiary of Quest Diagnostics, Inc. This approval will further expand OralDNA Labs' reach to the dentist community with the PST test.

"We are pleased to have met New York's standard for both our laboratory practices and our PST test. This approval by New York further supports our commitment to provide genetic tests that offer strong clinical value," said Lewis H. Bender, CEO, Interleukin Genetics. "PST along with our Heart Health now both meet New York State's unique criteria."

The PST Genetic Test provides a means of assessing an individual's genetic risk for periodontal disease, the most common cause of tooth loss. PST is the only genetic test available that is capable of identifying which patients are at increased risk for developing severe periodontal disease and can provide dentists and hygienists with important clinical information about their patients. The test is especially useful in patients with early signs of periodontal disease, including recurrent gingivitis and early-to-moderate periodontitis to identify patients more likely to develop severe periodontitis and associated complications.

About Periodontal Disease

Periodontal (gum) diseases, including gingivitis and periodontitis, are bacterially-induced chronic inflammatory diseases. Periodontitis affects the gums and bone supporting the teeth and if untreated or improperly treated can lead to tooth loss. Periodontal disease can affect one tooth or several, and is classified as mild, moderate or severe, based on clinical and radiographic evidence of loss of tissues that support the teeth. About a third of adults will have at least three to four teeth affected with moderate periodontal disease. It is well established that individuals who are smokers, have diabetes, or have IL-1 gene variations are at increased risk for more severe and generalized periodontitis. Periodontitis is usually first diagnosed by a dentist. In the U.S. there are over 160,000 dentists who frequently perform diagnostic (86 percent) and preventive (79 percent) procedures. The U.S. dental market is valued at $70 to $96 billion annually, with the average patient spending about $560 per year, over half of this on diagnostic and preventive procedures. Of the 128 million patients who visit a dentist each year, half are in the age range most appropriate for PST risk assessment. Additional information about periodontal disease may be found on the American Academy of Periodontology website at www.perio.org.

About PST Genetic Test

PST Genetic Test is a reliable way of assessing an individual's genetic risk for periodontal disease, the most common cause of tooth loss. PST Genetic Test is the first and only genetic test that analyzes interleukin 1 (IL1) genes for variations that identify an individual's predisposition for over-expression of inflammation and risk for more severe periodontal disease. The PST Genetic Test was developed following numerous clinical studies, and more than 40 peer-reviewed articles have been published on the test. PST is the only test shown in multiple long-term clinical studies to predict future tooth loss in dental patients.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests that empower consumers to prevent certain chronic diseases and that assist pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics is headquartered in Waltham, MA. For more information please visit www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements, including statements regarding the potential market for the PST Genetic Test. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company's annual report on Form 10-K for the year ended December 31, 2008, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.

SOURCE Interleukin Genetics, Inc.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin Genetics to Present Research Findings at Upcoming Medical Meetings
2. Interleukin Genetics Announces Strategic Divestment of Alan James Group
3. Interleukin Genetics Launches Inherent Health Brand of Genetic Tests Offering Clear and Personalized Insights to Wellness
4. Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting
5. Interleukin Genetics Reports First Quarter 2009 Financial Results
6. NYSE Amex Accepts Interleukin Genetics Plan to Meet Continued Listing Standards
7. Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
8. Interleukin Genetics Announces Conference Call to Discuss First Quarter 2009 Results
9. Interleukin Genetics Grants LABEC Pharma a License for Sales and Distribution of Its Heart Health Genetic Test
10. Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing Before the Listing Qualifications Panel
11. Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... 20, 2017 , ... Houston dentist , Dr. Nazari, ... at his office, Antoine Dental Center. Emergency dentistry encompasses many treatments for emergencies ... risk for serious complications and often experience severe pain. Not only does prompt ...
(Date:2/20/2017)... ... February 20, 2017 , ... Florida Hospital ... a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that breaks up life-threatening blood ... the Pepin Family Foundation. , “We greatly appreciate this gift from Constellation Brands. ...
(Date:2/19/2017)... RI (PRWEB) , ... February 19, 2017 , ... ... is proven to result in better care, and MEDfx and the Delaware Health ... state of Delaware. , As the nation’s first state-wide health information exchange, DHIN ...
(Date:2/18/2017)... ... 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing facility ... Ken was impressed with the safety and reliability of the Stannah Stairlift as well ... This endorsement by Ken Matthews can be heard on News Radio WHP 580 ...
(Date:2/18/2017)... ... 2017 , ... A new directory from the Senior Veterans ... connect elderly veterans of America's armed forces to a range of senior care ... on this year's increase in the Veterans Pension with Aid & Attendance for ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... FRANCISCO , February 20, 2017 ... expected to reach USD 58.4 billion by 2025, ... Research, Inc. The market is driven by technological ... serve future growth opportunities to the market. For ... with an aim of identifying emerging viruses and ...
(Date:2/20/2017)... LONDON , February 20, 2017 Acute, Chronic ... is expected to grow at a CAGR of 7% from 2016-2021 and ... a CAGR of 6% from 2016 to 2027. The market is estimated ... ... Read on to discover how you can exploit the future business ...
(Date:2/18/2017)... 17, 2017   Parker Waichman LLP, ... rights of victims injured by medical devices, comments ... call for better reporting. Congress required hospitals to ... concerns involving power morcellators and duodenoscopes prompted the ... how hospitals report injuries and deaths related to ...
Breaking Medicine Technology: